title: Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.
abstract: Ovarian cancer patients often suffer from malignant ascites and pleural effusion. Apart from worsening the outcome, this condition frequently impairs the quality of life in patients who are already distressed by ovarian cancer. This study investigated whether single intraperitoneal administration of the anti-VEGF antibody bevacizumab is capable of reducing the ascites-related body surface and prolonging survival. The study was performed in an orthotopic murine model of peritoneal disseminated platin-resistant ovarian cancer. Mice were treated with bevacizumab and/or paclitaxel or buffer (control). Reduction of body surface and increased survival rates were assessed as therapeutic success. Survival of mice in all treatment groups was significantly enhanced when compared to the non-treatment control group. The combination of paclitaxel plus bevacizumab significantly improved body surface as well as overall survival in comparison to a treatment with only one of the drugs. Treatment of malignant effusion with a single dose of bevacizumab as an intraperitoneal application, with or without cytostatic co-medication, may be a powerful alternative to systemic treatment.
authors: Department of Obstetrics and Gynaecology, University of Düsseldorf Medical Centre, D-40225 Düsseldorf, Germany.
authors: Daniel T
authors: DT
authors: Rein
authors: Anne Kathrin
authors: AK
authors: Volkmer
authors: Jens
authors: J
authors: Volkmer
authors: Ines M
authors: IM
authors: Beyer
authors: Wolfgang
authors: W
authors: Janni
authors: Markus C
authors: MC
authors: Fleisch
authors: Anne Kathrin
authors: AK
authors: Welter
authors: Dirk
authors: D
authors: Bauerschlag
authors: Thomas
authors: T
authors: Schöndorf
authors: Martina
authors: M
authors: Breidenbach